Tasly Pharmaceutical Group (600535.SH): TDX105 Granules Receive Drug Clinical Trial Approval
Tasly Pharmaceutical Group (600535.SH) announced that recently, the company received the "Drug Clinical Trial Approval Notice" for TDX105 Granules issued by the National Medical Products Administration (hereinafter referred to as the "NMPA").
Tasly Pharmaceutical Group (600535.SH) announced that the company recently received the Drug Clinical Trial Approval Notice for TDX105 Granules issued by the National Medical Products Administration (hereinafter referred to as the "NMPA").
TDX105 Granules is a Class 1.1 traditional Chinese medicine new drug developed based on a clinical experience formula from the Cancer Hospital of the Chinese Academy of Medical Sciences (National Cancer Center). The formulation composition, usage, and dosage of this product are consistent with the clinical application of the experience formula. This clinical experience formula has been used clinically for many years, and clinical observations show that it has a significant alleviating effect on itching, pain, and other skin damage caused by anti-tumor drug-related skin adverse reactions, with good efficacy and safety.
Related Articles
ZTE Corporation (00763) has received registration approval from the China Securities Regulatory Commission for the public issuance of corporate bonds to professional investors.
PRU (02378) repurchased 805,200 shares for a total of GBP 7.246 million on October 13.
Jiangsu Hengrui Pharmaceuticals (01276) repurchased 60,000 A shares for RMB 2.6965 million on October 14.
ZTE Corporation (00763) has received registration approval from the China Securities Regulatory Commission for the public issuance of corporate bonds to professional investors.
PRU (02378) repurchased 805,200 shares for a total of GBP 7.246 million on October 13.
Jiangsu Hengrui Pharmaceuticals (01276) repurchased 60,000 A shares for RMB 2.6965 million on October 14.
